JavaScript NENÍ povolen !

Prosím povolte JavaScript.

Článek

PubMed

Záznam pochází z PubMed

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Atherosclerosis. 2018 Oct ; 277 () : 234-255.

ISSN 1879-1484 | 0021-9150
Zdroj

Jazyk angličtina Země Irsko Médium print

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz https://www.medvik.cz/link/pmid30270054

PubMed 30270054
DOI 10.1016/j.atherosclerosis.2018.08.051
PII: S0021-9150(18)31359-5
Knihovny.cz E-zdroje

Klíčová slova
FHSC, Familial hypercholesterolaemia, Primary dyslipidaemia,
MeSH
anticholesteremika škodlivé účinky terapeutické užití MeSH
biologické markery krev MeSH
celosvětové zdraví * MeSH
disparity zdravotní péče MeSH
dostupnost zdravotnických služeb MeSH
fenotyp MeSH
genetická predispozice k nemoci MeSH
hyperlipoproteinemie typ II krev diagnóza epidemiologie terapie MeSH
kooperační chování MeSH
LDL-cholesterol krev MeSH
lidé MeSH
mezinárodní spolupráce * MeSH
prediktivní hodnota testů MeSH
prevalence MeSH
průzkumy zdravotní péče MeSH
rizikové faktory MeSH
separace krevních složek * škodlivé účinky MeSH
výsledek terapie MeSH
Check Tag
lidé MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH
Názvy látek
anticholesteremika MeSH
biologické markery MeSH
LDL-cholesterol MeSH

BACKGROUND AND AIMS: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. METHODS: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. RESULTS: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. CONCLUSIONS: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed.

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Najít záznam

Citační ukazatele

Možnosti archivace